Emerging technologies for the genomic analysis of cancer

por Nemunaitis, John, Senzer, Neil N
Publicado 2009

Reversible Masking Using Low-Molecular-Weight Neutral Lipids to Achieve Optimal-Targeted Delivery

por Templeton, Nancy Smyth, Senzer, Neil
Publicado 2012

Letter to the editor: Does Dicer Expression Affect shRNA processing?

por Senzer, Neil, Rao, Donald, Nemunaitis, John
Publicado 2009

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise

por Nemunaitis, John, Stanbery, Laura, Senzer, Neil
Publicado 2020

Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease

por Simmons, Olivia, Maples, Phillip B., Senzer, Neil, Nemunaitis, John
Publicado 2012

Procoagulant inhibitory properties of paclitaxel poliglumex

por Nemunaitis, John, Senzer, Neil, Cooper, Barry, Nemunaitis, Michael, Bedell, Cynthia, Singer, Jack W, Oldham, Fred B
Publicado 2010

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy

por Alqahtani, Ali, Choucair, Khalil, Ashraf, Mushtaq, Hammouda, Danae M, Alloghbi, Abduraham, Khan, Talal, Senzer, Neil, Nemunaitis, John
Publicado 2019

Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma

por Rao, Donald D., Jay, Christopher, Wang, Zhaohui, Luo, Xiuquan, Kumar, Padmasini, Eysenbach, Hilary, Ghisoli, Maurizio, Senzer, Neil, Nemunaitis, John
Publicado 2016

Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2)

por Jay, Chris, Nemunaitis, Gregory, Nemunaitis, John, Senzer, Neil, Hinderlich, Stephan, Darvish, Daniel, Ogden, Julie, Eager, John, Tong, Alex, Maples, Phillip B
Publicado 2008

KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex

por Rao, Donald D., Luo, Xiuquan, Wang, Zhaohui, Jay, Christopher M., Brunicardi, Francis C., Maltese, William, Manning, Luisa, Senzer, Neil, Nemunaitis, John
Publicado 2018

Notch1 Activation Up-Regulates Pancreatic and Duodenal Homeobox-1

por Liu, Shi-He, Zhou, Guisheng, Yu, Juehua, Wu, James, Nemunaitis, John, Senzer, Neil, Dawson, David, Li, Min, Fisher, William E., Brunicardi, F. Charles
Publicado 2013

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

por Kaufman, Howard L., Amatruda, Thomas, Reid, Tony, Gonzalez, Rene, Glaspy, John, Whitman, Eric, Harrington, Kevin, Nemunaitis, John, Zloza, Andrew, Wolf, Michael, Senzer, Neil N.
Publicado 2016

Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance

por Oh, Johnathan, Barve, Minal, Senzer, Neil, Aaron, Phylicia, Manning, Luisa, Wallraven, Gladice, Bognar, Ernest, Stanbery, Laura, Horvath, Staci, Manley, Meghan, Nemunaitis, John, Walter, Adam, Rocconi, Rodney P.
Publicado 2020

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

por Eager, Robert M, Cunningham, C Casey, Senzer, Neil N, Stephenson, Joe, Anthony, Stephen P, O'Day, Steven J, Frenette, Gary, Pavlick, Anna C, Jones, Barry, Uprichard, Margaret, Nemunaitis, John
Publicado 2009

Safety and in vivo Expression of a GNE-Transgene: A Novel Treatment Approach for Hereditary Inclusion Body Myopathy-2

por Phadke, Anagha P., Jay, Chris, Chen, Salina J., Haddock, Courtney, Wang, Zhaohui, Yu, Yang, Nemunaitis, Derek, Nemunaitis, Gregory, Templeton, Nancy S., Senzer, Neil, Maples, Phillip B., Tong, Alex W., Nemunaitis, John
Publicado 2009

Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melan...

por Andtbacka, Robert HI, Collichio, Frances A, Amatruda, Thomas, Senzer, Neil, Chesney, Jason, Delman, Keith, Spitler, Lynn, Puzanov, Igor, Agarwala, Sanjiv, Milhem, Mohammed, Harrington, Kevin, Middleton, Mark, Li, Ai, Shilkrut, Mark, Coffin, Robert, Kaufman, Howard
Publicado 2014

Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma

por Ghisoli, Maurizio, Barve, Minal, Schneider, Reva, Mennel, Robert, Lenarsky, Carl, Wallraven, Gladice, Pappen, Beena O, LaNoue, John, Kumar, Padmasini, Nemunaitis, Derek, Roth, Alyssa, Nemunaitis, James, Whiting, Sam, Senzer, Neil, Fletcher, Frederick A, Nemunaitis, John
Publicado 2015

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

por Rocconi, Rodney P., Stanbery, Laura, Tang, Min, Madeira da Silva, Luciana, Walter, Adam, Monk, Bradley J., Herzog, Thomas J., Coleman, Robert L., Manning, Luisa, Wallraven, Gladice, Horvath, Staci, Bognar, Ernest, Senzer, Neil, Brun, Scott, Nemunaitis, John
Publicado 2023

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

por Rocconi, Rodney P., Stanbery, Laura, Tang, Min, Madeira da Silva, Luciana, Walter, Adam, Monk, Bradley J., Herzog, Thomas J., Coleman, Robert L., Manning, Luisa, Wallraven, Gladice, Horvath, Staci, Bognar, Ernest, Senzer, Neil, Brun, Scott, Nemunaitis, John
Publicado 2022

PDX-1 Is a Therapeutic Target for Pancreatic Cancer, Insulinoma and Islet Neoplasia Using a Novel RNA Interference Platform

por Liu, Shi-He, Rao, Donald D., Nemunaitis, John, Senzer, Neil, Zhou, Guisheng, Dawson, David, Gingras, Marie-Claude, Wang, Zhaohui, Gibbs, Richard, Norman, Michael, Templeton, Nancy S., DeMayo, Francesco J., O'Malley, Bert, Sanchez, Robbi, Fisher, William E., Brunicardi, F. Charles
Publicado 2012